Cargando…
Expression of the leukemic prognostic marker CD7 is linked to epigenetic modifications in chronic myeloid leukemia
BACKGROUND: Expression levels of the cell surface glycoprotein, CD7, and the serine protease, elastase 2 (ELA2), in the leukemic cells of patients with chronic myeloid leukemia (CML) have been associated with clinical outcome. However, little is known about the mechanisms that underlie the variable...
Autores principales: | Rogers, Sally L, Zhao, Yun, Jiang, Xiaoyan, Eaves, Connie J, Mager, Dixie L, Rouhi, Arefeh |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2843654/ https://www.ncbi.nlm.nih.gov/pubmed/20175919 http://dx.doi.org/10.1186/1476-4598-9-41 |
Ejemplares similares
-
Stem Cell Biomarkers in Chronic Myeloid Leukemia
por: Jiang, Xiaoyan, et al.
Publicado: (2008) -
Deregulation of the CDX2-KLF4 axis in acute myeloid leukemia and colon cancer
por: Rouhi, Arefeh, et al.
Publicado: (2013) -
Targeting AXL kinase sensitizes leukemic stem and progenitor cells to venetoclax treatment in acute myeloid leukemia
por: Niu, Xiaojia, et al.
Publicado: (2021) -
Evidence for high bi-allelic expression of activating Ly49 receptors
por: Rouhi, Arefeh, et al.
Publicado: (2009) -
Epigenetic Modifications in Acute Myeloid Leukemia: Prognosis, Treatment, and Heterogeneity
por: Goldman, Samantha L., et al.
Publicado: (2019)